Ceftolozane plus tazobactam is an antipseudomonal cephalosporin combined with tazobactam, an established beta-lactamase inhibitor, and has in vitro potency against a range of clinically important ␤-lactamase-producing bacteria, including most extended-spectrum-␤-lactamase (ESBL)-positive Enterobacteriaceae. The pharmacodynamics of ␤-lactam-␤-lactamase inhibitor combinations presents a number of theoretical and practical challenges, including modeling different half-lives of the compounds. In this study, we studied the pharmacodynamics of ceftolozane plus tazobactam against Escherichia coli and Pseudomonas aeruginosa using an in vitro pharmacokinetic model of infection. Five strains of E. coli, including three clinical strains plus two CTX-M-15 (one high and one moderate) producers, and five strains of P. aeruginosa, including two with OprD overexpression and AmpC ␤-lactamases, were employed. Ceftolozane MICs (E. coli, 0.12 to 0.25 mg/liter, and P. aeruginosa, 0.38 to 8 mg/ liter) were determined in the presence of 4 mg/liter tazobactam. Dose ranging of ceftolozane (percentage of time in which the free-drug concentration exceeds the MIC [fT>MIC], 0 to 100%) plus tazobactam (human pharmacokinetics) was simulated every 8 hours, with half-lives (t 1/2 ) of 2.5 and 1 h, respectively. Ceftolozane and tazobactam concentrations were confirmed by high-performance liquid chromatography (HPLC). The ceftolozane-plus-tazobactam fT>MIC values at 24 h for a static effect and a 1-log and 2-log drop in initial inoculum for E. coli were 27.8% ؎ 5.6%, 33.0% ؎ 5.6%, and 39.6% ؎ 8.5%, respectively. CTX-M-15 production did not affect the 24-h fT>MIC for E. coli strains. The ceftolozane-plus-tazobactam fT>MIC values for a 24-h static effect and a 1-log and 2-log drop for P. aeruginosa were 24.9% ؎ 3.0%, 26.6% ؎ 3.9%, and 31.2% ؎ 3.6%. Despite a wide range of absolute MICs, the killing remained predictable as long as the MICs were normalized to the corresponding fT>MIC. Emergence of resistance on 4؋ MIC plates and 8؋ MIC plates occurred maximally at an fT>MIC of 10 to 30% and increased as time of exposure increased. The fT>MIC for a static effect for ceftolozane plus tazobactam is less than that observed with other cephalosporins against E. coli and P. aeruginosa and is more similar to the fT>MIC reported for carbapenems.
C
eftolozane plus tazobactam is a novel antibacterial consisting of a combination of the new cephalosporin ceftolozane with a well-established ␤-lactamase inhibitor, i.e., tazobactam. The combination has completed phase 3 clinical trials for complicated intra-abdominal and complicated urinary tract infections (1, 2) . It was recently approved in the United States for these indications and is undergoing regulatory review in the European Union.
The in vitro potency of ceftolozane plus 4 mg/liter tazobactam has been studied against Pseudomonas aeruginosa and members of the Enterobacteriaceae from the United States and Europe (3) (4) (5) . Ceftolozane plus tazobactam was the most active ␤-lactam agent when tested against multidrug-resistant P. aeruginosa and Enterobacteriaceae (6); however, due to ceftolozane's stability to pseudomonal AmpC beta-lactamase, the addition of tazobactam produced only a marginal improvement in potency against P. aeruginosa. Similar observations were made with multiresistant and ␤-lactam-resistant clinical isolates (7, 8) . In contrast, against extended-spectrum-␤-lactamase (ESBL)-producing and/or ceftazidime-resistant Escherichia coli, Klebsiella pneumoniae, and Proteus sp., MIC 50 values of Ն32 mg/liter for ceftolozane alone were reduced to 1 to 4 mg/liter by the addition of tazobactam. The pharmacodynamics of ceftolozane plus tazobactam has been studied in a neutropenic murine thigh infection model and in vitro models. The dominant pharmacodynamic index was the percentage of time in which the free-drug concentration exceeded the MIC (fTϾMIC), and the fTϾMIC for 24-h static effect was 26.3 Ϯ 2.1% for Enterobacteriaceae (4 strains) and 24.0 Ϯ 3.3% for P. aeruginosa (4 strains). The equivalent magnitudes for a 1-log kill were 31.6 Ϯ 1.6% and 31.5 Ϯ 3.9%, respectively (9) . These values are lower than the 30 to 40% fTϾMIC bacteriostatic targets often associated with cephalosporins and may be related to ceftolozane's penicillin-binding protein affinity, with the increased bactericidal activity being more like that of carbapenems.
The objective of this study was to determine the fTϾMIC targets for antibacterial effect, as measured by the extent of bacterial killing and changes in population profiles at 24 h, 48 h, and 72 h of ceftolozane plus tazobactam against a range of Enterobacteriaceae and P. aeruginosa isolates with and without production of ESBL and other ␤-lactamases.
MATERIALS AND METHODS

Pharmacokinetics.
A FerMac 310 fermentation system (Electrolab, Tewkesbury, England) in vitro pharmacokinetic model (as previously described [24] ) was used to simulate fTϾMIC (0 to 100%) of free (unbound) ceftolozane (TOL) for each strain over 72 h when administered every 8 h, i.e., total of 9 doses (10). The pharmacokinetic profile from ceftolozane plus tazobactam (TAZ) as a 2:1 mg:mg ratio produces a TOL/TAZ serum concentration ratio of 2.9:1 (11) . Initially, in the dose-ranging experiments, tazobactam was dosed at a fixed ceftolozane-tazobactam ratio of 2.9:1. In subsequent experiments, tazobactam given intravenously every 8 h was dosed at human pharmacokinetic concentrations associated with a 500 mg dose (maximum concentration of free/unbound drug of 18.0 mg/liter) (12) . Due to the difference in half-lives between ceftolozane and tazobactam (2.5 h and 1 h, respectively), the model was supplemented with ceftolozane (12.5 ml/h) throughout each dosing period via a separate dosing chamber to achieve the required concentration-time profile. The ceftolozane freedrug concentrations used were based on total drug concentration-time profiles from healthy volunteers (protein binding, 20%) (11) . Tazobactam free-drug concentrations were based on protein binding of 20% (12) . The simulated half-lives of ceftolozane and tazobactam were 2.5 h and 1 h, respectively.
Media and bacterial counting. Mueller-Hinton broth (100%; Thermo Fisher, Basingstoke, England) was used in all experiments. Nutrient agar plates (Thermo Fisher, Basingstoke, England) were used to recover bacterial strains from the model. Carbapenemase (kindly supplied by J. Spencer, Bristol University, Bristol, United Kingdom) was used to neutralize ceftolozane. The carbapenemase neutralized ceftolozane up to a concentration of 50 g/ml. Aliquots of 1 ml each were taken from the central compartment at 0, 1, 2, 3, 4, 5, 6, 7, 12, 24, 25, 26, 27, 28, 29, 30, 31, 36, 48, 60 , and 72 h, treated with 10 l of carbapenemase, left for 20 min, and then plated on nutrient agar plates using a spiral plater (Don Whitley Scientific, Yorkshire, United Kingdom) for determination of total bacterial counts. A second aliquot not treated with carbapenemase was plated on nutrient agar plates containing 1ϫ, 2ϫ, 4ϫ, and 8ϫ the MIC of ceftolozane and tazobactam (4 mg/liter) for the strain tested to detect changes in population profile. Any isolates grown on these plates were stored at Ϫ70°C and subsequently had their ceftolozanetazobactam (4 mg/liter) MIC determined by agar dilution using the CLSI method, which was modified to produce a linear series of dilutions (13) . Ceftolozane-tazobactam MICs were assessed by concurrent agar dilution MIC testing of single survivors at 72 h and of parental (naive) strains. The risk of emergence of resistance was stratified by the percent fTϾMIC.
Bacteria. Five strains of E. coli and five strains of P. aeruginosa were tested ( Table 1 ). The initial inoculum used was 1 ϫ 10 6 CFU/ml. MICs were determined in duplicate on all strains as described by CLSI using microdilution methodology with the exception that linear dilutions were used instead of traditional 2-fold dilutions. Antibiotic assay. Ceftolozane and tazobactam concentrations were measured by HPLC. The stationary phase for both compounds was Gemini-NX 5uC18 (100 by 4.6 mm; Phenomenex, Macclesfield, United Kingdom). The mobile phase composition was 98% phosphate buffer, 1% acetonitrile, 1% orthophosphoric acid. The wavelength was 254 nm for ceftolozane and 220 nm for tazobactam; detection was by UV absorbance using a Dionex UltiMate 3000 variable-wavelength detector (Thermo Fisher, Hemel Hempstead, United Kingdom), and the flow rate was 1.8 ml/min. Aqueous samples (10 l) were injected, and the retention was approximately 5 to 6 min for ceftolozane and 3 to 4 min for tazobactam. The standard curve concentration range was 0 to 50 mg/liter for both ceftolozane and tazobactam.
Data analysis. The relationship between fTϾMIC and antibacterial effect for each strain as described by log reduction in viable count at 24, 48, and 72 h were delineated using a Boltzmann sigmoid Emax equation: y ϭ bottom ϩ (top Ϫ bottom)/{1 ϩ exp[(V50 Ϫ x)/slope]} using the software package GraphPad Prism version 4 (San Diego, CA, USA). The combined data for all E. coli strains and the combined P. aeruginosa strains were plotted using GraphPad Prism giving a pooled fTϾMIC where possible, using a top-to-bottom variable-slope equation:
Emergence of resistance. Changes in population analysis profiles for each strain were assessed by growth on plates containing 2ϫ, 4ϫ, and 8ϫ the ceftolozane MIC plus 4 mg/liter tazobactam. Colonies growing on the 4ϫ and 8ϫ MIC plates were subsequently assessed for MIC change at 72 h. 
RESULTS
MICs.
The MICs for the individual E. coli strains and P. aeruginosa strains with the ␤-lactamases present are shown in Table 1 .
Relationship between methods of tazobactam dosing and antibacterial effect. Dosing tazobactam at a fixed ratio (2.9:1) with ceftolozane to achieve a TϾMIC range of 0 to 100% against an ESBL-producing E. coli strain (49439) resulted in unexpectedly high TϾMIC values (81.9%). It was concluded that there was insufficient tazobactam present to protect the strain from the ␤-lactamase present. Dosing tazobactam as a continuous infusion at 4 mg/liter reduced the TϾMIC to 26.2%; using mean tazobactam human pharmacokinetics provided sufficient protection (TϾMIC of 24.4%). Subsequent experiments all used mean tazobactam human pharmacokinetic profiling.
Pharmacokinetic curves. There was good correlation between the target and measured ceftolozane and tazobactam concentrations; the interday coefficient of variation (CV) was 4.2% for ceftolozane and 7.7% for tazobactam, showing that we were able to accurately concurrently model the different half-lives of the two drugs. The lower limit of detection was 1.0 mg/liter for both compounds. Figures 1 and 2 show scatter plots of the predicted and observed ceftolozane and tazobactam concentrations. Linearity of the ceftolozane assay is shown by the equation y ϭ 5.5318x ϩ 2.5709, and r 2 was 0.9746; for tazobactam, y ϭ 1.8432x ϩ 0.0602, and r 2 was 0.9996. The actual half-life simulated was 2.7 h for ceftolozane and 1.064 h for tazobactam.
Relationship between fT>MIC and antibacterial effect. There was a clear relationship between antibacterial effect and fTϾMIC for all strains. The fTϾMIC values for a static effect and for 1-log, 2-log, and 3-log reductions in counts of each strain plus mean data for E. coli and P. aeruginosa strains are shown in Tables  2 and 3 . The fTϾMIC relationship to antibacterial effect (log change in viable count compared) for the combined E. coli strains (n ϭ 5) at 24, 48, and 72 h is shown in Table 2 , and that for all P. aeruginosa strains (n ϭ 5) is shown in Table 3 .
There was an excellent curve fit between fTϾMIC and antibacterial effect, with r 2 values for the pooled E. coli strains being greater than 0.9700 at 24, 48, and 72 h. For P. aeruginosa at 24 and 48 h, all r 2 values were greater than 0.93 except for P. aeruginosa 47235 (0.6698 at 48 h). At 72 h, the relationship between antibacterial effect and fTϾMIC was variable, and this was reflected in the curve values, which ranged from 0.3014 to 0.9919.
At 24 h, the fTϾMIC for a static effect for E. coli strains ranged from 22.0 to 36.6%. The E. coli strain with higher ceftolozanetazobactam MICs (0.25 mg/liter) had an antibacterial effect response similar to that of the strains with MICs of 0.12 mg/ liter. The mean fTϾMIC for a static effect and for 1-, 2-, and 3-log reductions in viable count increased from 27.8% Ϯ 5.6% to 33.0% Ϯ 5.5% and from 39.4% Ϯ 8.9% to 44.2% Ϯ 11.2%, respectively. The mean fTϾMIC for static effect increased from 27.8% Ϯ 5.6% at 24 h to 50.2% Ϯ 8.6% at 48 h, and as time increased, the fTϾMIC increased for each antibacterial effect measure (Table 2 ; Fig. 2 ). Neither the resistance mechanism nor the MIC affected the fTϾMIC values; strains 47202 and 49439, containing CTX-M ESBLs, showed an antibacterial effect comparable to that seen in the strains without these enzymes ( Fig. 3 and 4) .
A similar pattern of exposure response was observed with P. aeruginosa strains at 24 h; the fTϾMIC for a static effect ranged from 20.7 to 27.8% (Table 3 ). The two P. aeruginosa strains with higher ceftolozane-tazobactam MICs (6.0 and 8.0 mg/liter) had antibacterial effect responses similar to those of strains with MICs of 0.38, 0.5, and 1 mg/liter, demonstrating that the TϾMIC is consistent across a range of MICs. The mean fTϾMIC for a static effect and for 1-and 2-log reductions in viable count at 24 h increased from 24.9% Ϯ 3.0% to 26.6% Ϯ 3.9% to 31.2% Ϯ 3.7%, respectively (Table 2 ). Only two of the five strains tested demonstrated a 3-log reduction in viable count.
Increased exposure had a variable effect on the fTϾMIC; the static mean fTϾMIC decreased slightly from 24.9% at 24 h to 24.1% at 48 h. For strain 47235 at 48 h, the combination did not produce a static effect, and the fTϾMIC increased from 20.7% to 47.8% for strain 17286. At 48 h, the ceftolozane-tazobactam combination achieved a 2-log reduction in viable count against strain 38475 alone, and at 72 h this was reduced to a static effect and a 1-log reduction in bacterial count ( Table 2) . Emergence of resistance. Tables 4 and 5 show the risk of emergence as stratified by fTϾMIC over time (24 to 72 h) for E. coli and P. aeruginosa, respectively. As time increased, the number of CFU/ml increased; at 24 h, E. coli strains produced growth on 4ϫ MIC plates at fTϾMIC values of 10 to 30%. No growth was observed at a fTϾMIC of Ն40%; no growth occurred on 8ϫ MIC plates. At 48 h, growth was noted on 8ϫ MIC plates up to a fTϾMIC of 40%. At 72 h, a maximum risk of resistance was seen at a fTϾMIC of 30%. Growth on 8ϫ MIC plates was seen at 60% in 1/4 experiments. P. aeruginosa experiments showed increased risk of resistance at fTϾMIC values of 10 to 60% at 24 h on 4ϫ MIC plates (2/5 experiments; 4 log 10 ) ( Table 5 ); 1/5 experiments showed growth on 8ϫ MIC plates at a fTϾMIC of 40%. At 48 h, growth was observed at a fTϾMIC of 100% on 4ϫ and 8ϫ MIC plates in 1/5 experiments; maximum growth was seen at a fTϾMIC of 20 to 40%. A similar pattern was seen at 72 h.
MICs were determined for the parent strains and progeny growing on 4ϫ or 8ϫ MIC plates at 72 h. Testing by agar dilution MIC showed increases in the ceftolozane MIC alone and in the ceftolozane-tazobactam MIC of the progeny ranging from 3ϫ to more than 16ϫ the original MIC. Strain 47202 (CTX-M-15) showed the greatest increase in MIC (16ϫ). It is unclear what the change in resistance mechanism(s) is, as we have not characterized the strains.
DISCUSSION
The pharmacodynamics of cephalosporins against E. coli and Pseudomonas aeruginosa is well described, with fTϾMIC (as a percentage) for a static effect being the established pharmacodynamic index relating to clinical efficacy (14) (15) (16) . It is accepted that a TϾMIC of 35 to 40% is associated with a 24-h bacteriostatic effect for aerobic Gram-negative rods and that higher TϾMIC values are linked with bactericidal drug activity for cephalosporins (www .eucast.org).
The data in this study reaffirm this relationship, with an excellent correlation between fTϾMIC and antibacterial effect for ceftolozane plus tazobactam with E. coli and P. aeruginosa.
The fTϾMIC values for ceftolozane plus tazobactam at 24 h for a static effect and for 1-log 10 and 2-log 10 drops in initial inoculums for E. coli were 27.8% Ϯ 5.6%, 33.0% Ϯ 5.6%, and 39.6% Ϯ 8.6%, respectively. The ceftolozane-tazobactam fTϾMIC values for a 24-h static effect and for 1-log 10 and 2-log 10 drops in CFU count for P. aeruginosa were 24.9 Ϯ 3.0%, 26.6 Ϯ 3.9%, and 31.2 Ϯ 3.6%. These data support data obtained by Craig and Andes (9) in a murine neutropenic thigh model using susceptible Gram-negative bacilli and ESBL-containing E. coli. They reported a mean fTϾMIC of 26.3% Ϯ 2.1% for a static effect with cephalosporinsusceptible strains, and for ESBL-containing strains, a fTϾMIC of 31.1% Ϯ 4.4% for a static effect was observed (9) . In our study, we observed similar 24-h static effect and 1-and 2-log 10 kill values for E. coli strains containing ESBLs and non-ESBL strains. In similarly designed experiments with razupenem and Enterobacteriaceae, the fTϾMIC values for the Enterobacteriaceae strains we tested were 27.5% to 47% (34.2% Ϯ 7.6%) for a bacteriostatic effect at 24 h and 42.3% to 64.1% (42.5% Ϯ 7.8%) for a 2-log-unit reduction in count, which is in keeping with the published literature on carbapenems (17) . The increase in the fTϾMIC threshold as time increases has been observed in previous studies with other cephalosporins; e.g., previous data obtained by using ceftaroline against four strains of E. coli showed an increase in the static fTϾMIC from 35.0% Ϯ 6.3% at 24 h to 40.7% Ϯ 4.7% at 48 h, 47.1% Ϯ 1.6% at 72 h, and 48.1% Ϯ 16.1% at 96 h (K. E. Bowker, unpublished data). The increase in TϾMIC may be due to initial killing of more susceptible colonies within the population.
The fTϾMIC values for a static effect for P. aeruginosa were similar to those for E. coli with a mean value of 24.9%. The 1-log and 2-log 10 drops in CFU were lower than those for E. coli at 26.6% and 31.2%, respectively; again, these figures are similar to those reported by Craig and Andes (9), who cited values of 24% Ϯ 3.3% and 31.5% Ϯ 3.9% (n ϭ 4), but somewhat lower than those reported by Lepak et al. (18) , who tested 12 strains of P. aeruginosa and reported a TϾMIC for static effect of 31.2% Ϯ 6.99% and a value for a 1-log drop in count of 39.4% Ϯ 7.53%. The fTϾMIC threshold did not change with change in MIC. For P. aeruginosa 34845, the fTϾMIC for static effect was 23.0%, markedly lower than the value (37%) we previously reported for doripenem for the same strain (22) . In that study, the mean fTϾMIC for 3 strains was 25.0% Ϯ 11% for a static effect. Ceftolozane plus tazobactam appears to be more carbapenemlike than cephalosporin-like in its activity. Bulik et al. (23) , using a range of Gram-negative bacteria, including ESBL producers and P. aeruginosa (ceftolozane-tazobactam MICs of 1 to 64 mg/liter and piperacillin-tazobactam MICs of 8 to 64 mg/liter), reported that a TϾMIC of Ն37.5% resulted in a 1-to 3-log 10 reduction in bacterial count after 24 h for strains with MICs of Յ16 mg/liter. However, they concluded that ceftolozane plus tazobactam had improved efficacy over that of piperacillin plus tazobactam. The higher fTϾMIC target in their study could be due to study design; however, our own data with piperacillin-tazobactam against P. aeruginosa, obtained with the model used in this study, indicated fTϾMIC values of 39.8% Ϯ 3.3% for a static effect and 62.8% Ϯ 17.7% for a 2-log reduction in inoculum, suggesting that ceftolozane plus tazobactam is pharmacodynamically superior to piperacillin plus tazobactam (19) .
VanScoy et al. took a different approach, focusing on the protective capacity of tazobactam (20) . They reported times above the tazobactam threshold of 35, 50, and 75%, respectively, for a static effect and for 1-log and 2-log reductions in counts of isogenic CTX-M-15-producing E. coli at 24 h. Our initial data concur that if insufficient tazobactam was present, it would not protect against CTX-M-producing strains. In this study, we tested only E. coli; however, we recently observed that the fTϾMIC exposure varies within the Enterobacteriaceae (21) . fTϾMIC values for a 24-h bacteriostatic effect were similar for ceftaroline against E. coli (35.0% Ϯ 6.3%), K. pneumoniae (36.1% Ϯ 8.3%), and Proteus mirabilis (39.1% Ϯ 26.4%). Values were higher with Citrobacter and Serratia spp. In addition there was much more strain-to-strain variation within the Proteus strains than E. coli and K. pneumoniae, while K. pneumoniae required much higher fTϾMIC values for a 2-log or 3-log kill than E. coli. Hence, it is not clear to what extent observations on E. coli can be extrapolated to the entire family of Enterobacteriaceae.
The target required for prevention of emergence of resistance is much greater than that required for a static effect or a 1-log 10 reduction and also increases as time increases. The maximum risk of resistance generally occurred at a fTϾMIC around 30% for E. coli, which is similar to the target static fTϾMIC. The standard dosing of ceftolozane plus tazobactam would achieve a fTϾMIC much higher than this figure. Population analysis profiles with razupenem and Enterobacteriaceae indicated growth on recovery media with 2ϫ, 4ϫ, and 8ϫ MIC at fTϾMICs in the range of 1% to 69% but rarely at values of Ն70%. In our previous study using doripenem and P. aeruginosa, we were unable to suppress resistance even using doses of 4ϫ to 6ϫ those used in human studies. Similarly, in this study we were unable to suppress resistance even with a fTϾMIC of 100% for P. aeruginosa. The relationship between fTϾMIC and changes in population profiles for both E. coli and P. aeruginosa species and ceftolozane-tazobactam is similar to that seen in previous studies with E. coli and P. aeruginosa using our in vitro model (17, 19) .
In conclusion, this study confirms that fTϾMIC predicts the ceftolozane-tazobactam antibacterial effect and that the pharmacokinetic/pharmacodynamic targets are similar for E. coli and P. aeruginosa. The target required for static effect is lower than the 30 to 40% fTϾMIC targets often associated with cephalosporins and may be related to ceftolozane's increased bactericidal activity, which is more like that of carbapenems. Furthermore, ESBL production and strain differences in MICs did not affect fTϾMIC. Finally, the method used for assessing the effect of a ␤-lactam inhibitor against strains containing an enzyme(s) is important and may affect data and conclusions.
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